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The gastrointestinal tract is increasingly viewed as critical in controlling glucose 
metabolism, because of its role in secreting multiple glucoregulatory hormones, such 
as glucagon like peptide-1 (GLP-1). Here we investigate the molecular pathways 
behind the GLP-1- and insulin-secreting capabilities of a novel GPR119 agonist, 
Oleoyl-Lysophosphatidylinositol (Oleoyl-LPI). Oleoyl-LPI is the only LPI species able 
to potently stimulate the release of GLP-1 in vitro, from murine and human L-cells, and 
ex-vivo from murine colonic primary cell preparations. Here we show that Oleoyl-LPI 
mediates GLP-1 secretion through GPR119 as this activity is ablated in cells lacking 
GPR119 and in colonic primary cell preparation from GPR119-/- mice. Similarly, 
Oleoyl-LPI-mediated insulin secretion is impaired in islets isolated from GPR119-/- 
mice. On the other hand, GLP-1 secretion is not impaired in cells lacking GPR55 in 
vitro or in colonic primary cell preparation from GPR55-/- mice. We therefore conclude 
that GPR119 is the Oleoyl-LPI receptor, upstream of ERK1/2 and cAMP/PKA/CREB 
pathways, where primarily ERK1/2 is required for GLP-1 secretion, while CREB 
activation appears dispensable. 
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The hormone glucagon-like peptide-1 (GLP-1) is released from the intestine under 
postprandial conditions and it stimulates insulin secretion from the pancreatic β-cell in 
a glucose-dependent manner. Although GLP-1 mimics are already being used in the 
clinic to treat type 2 diabetic (T2D) patients, these have raised several safety issues such 
as risk of developing pancreatitis and medullary carcinoma of the thyroid [1]. 
Therefore, an alternative strategy, based on the possibility to increase endogenous GLP-
1 secretion rather than administering exogenous GLP-1, is an attractive therapeutic 
option. It has been reported that glucose-stimulated insulin secretion (GSIS) of GLP-1 
can be further modulated by amino acids, fatty acids and lipids [2-4]. Interestingly, 
most of the endogenous GLP-1 secretion is suggested to be mediated by G protein-
coupled receptors (GPCRs) such as GPR119 [5, 6], GPR40 [7] and GPR120 [8]. Of 
these three, GPR119 seems to be the most important inducer of gastric inhibitory 
polypeptide or glucose-dependent insulinotropic peptide (GIP) and GLP-1 secretion 
after fat ingestion [9]. GPR119 is a member of class A GPCRs, which can bind to long-
chain fatty acids including oleoylethanolamide (OEA), 2-oleoylglycerol (2-OG) and 
lysophosphatidylcholine (LPC) [6]. The expression of GPR119 mRNA has been 
reported in a number of tissues including brain, heart, spleen and stomach [10, 11]. The 
highest level of GPR119 expression has been reported in islets of Langerhans, 
pancreatic β-cell lines, and intestinal L-cells [12, 13]. Activation of GPR119 has been 
shown to positively modulate incretins and insulin secretion in humans [4, 14]. In 
rodents, this effect results in reduction of food intake and body weight gain [15, 16]. 
GPR119 expression in pancreatic β-cells led to the hypothesis that this receptor could 
play a role in modulating insulin secretion. Therefore, GPR119 agonists, which have 
been shown to raise intracellular cyclic AMP (cAMP) levels in vitro in different 
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pancreatic β-cell systems expressing endogenous GPR119, would be expected to 
potentiate GSIS in a similar manner as GLP-1 and GIP, hormones which also act via 
GPCRs in β-cells. The insulinotropic actions of GPR119 agonists have been 
demonstrated in different models of pancreatic β-cells [17]. Although OEA has been 
identified as the main ligand for GPR119, other phospholipids such as 
lysophospholipids are potential ligands for this receptor [11]. The lysophospholipid 
lysophosphatidylinositol (LPI), initially discovered as ligand for GPR55 [18], has 
multiple GPR55-independent physiological and pathological roles [19]. 
In this study, we describe the role of a specific species of LPI in the secretion of GLP-
1 from enteroendocrine L-cells and primary cell preparations. We further demonstrate 
the specific role of GPR119 in LPI-dependent GLP-1 secretion. To achieve this, we 
downregulated GPR119 and GPR55 protein expression in vitro through specific 
siRNAs and we used colonic primary preparations from GPR55-/- and GPR119-/- 
transgenic mouse models in ex vivo experiments. Investigation of the Oleoyl-LPI-
induced GLP-1 secretion mechanism revealed that GPR119 activation regulates GLP-
1 secretion through a pathway dependent on the phosphorylation of extracellular signal-
regulated kinase (ERK)1/2 and stimulation of a cAMP/protein kinase A (PKA)-
dependent pathway.  
 
 
2. Materials and methods 
2.1 Reagents  
Different LPI species were purchased from Avanti® Polar Lipids, USA. Stocks were 
dissolved in methanol:chloroform (M:C) and stored at -20oC in nitrogen atmosphere. 
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Oleoylethanolamide (OEA), DPP-IV inhibitor (KR-62436), CID16020046 and 
PD98059 from Sigma-Aldrich, UK, were dissolved in DMSO. The OEA used for the 
cAMP experiment, from Cayman Chemical, USA, and H-89 (from Santa Cruz 
Biotechnology, USA) were dissolved in DMSO.  
GeneJET RNA Purification Kit, Maxima Reverse Transcription Kit and Maxima SYBR 
Green/ROX qPCR Master Mix Kit were purchased from Thermo Fisher Scientific, 
USA. Primary antibodies used for immunoblotting were: anti GPR119 from Santa Cruz 
Biotechnology, USA, anti GPR55 from Cayman Chemical, USA, anti α-Tubulin from 
Sigma-Aldrich, UK, anti phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) from 
Cell Signaling Technology, USA, and anti phospho-CREB (Ser133) from R&D 
Systems, USA. 
Animal use for this study was approved by the Animal Ethics Committee of Curtin 
University, and all procedures were carried out in accordance to NIH guidelines, No. 
8023, revised 1978. 
 
2.2 Cell culturing 
NCI-H716 cells were maintained in 75 cm2 tissue culture flasks (Corning® Costar®) 
in RPMI 1640 media containing 2.0 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 
mM HEPES buffer, 1.0 mM sodium pyruvate, and 4.5 g/L glucose and supplemented 
with 10% FBS. When plating for an experiment, cell adhesion and endocrine 
differentiation were initiated by growing cells in dishes coated with growth factor 
reduced MatrigelTM diluted at the ratio of 1:2 (Becton Dickinson, USA) in high-glucose 
Dulbecco´s modified Eagle medium (DMEM), 10% FBS, 2 mM glutamine, 100 IU/ml 
penicillin and 100 μg/ml streptomycin. GLUTag cells were maintained in low glucose 
DMEM (Sigma-Aldrich, UK) (1g/L) containing 2 mM L-glutamine, 1 mM sodium 
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pyruvate supplemented with 10% FBS, 100 IU/ml penicillin and 100 μg/ml 
streptomycin. COS-7 cells were cultured in DMEM supplemented with 10% FBS, 2 
mM L-glutamine, 100IU/ml penicillin and 100 μg/ml streptomycin (Thermo Fisher 
Scientific, USA).   
 
2.3 siRNA Transfection 
GLUTag and NCI-H716 cells transfection was performed according to the 
“Lipofectamine® 2000 transfection protocol” (Thermo Fisher Scientific, USA) and 
optimised for a 6-well plate format. Briefly, cells were plated in complete growth 
medium at a density of 3.0 x 105 / well in a 6-well plate and incubated at 37°C/5% CO2. 
Twenty-four hours later, 300nM of total siRNA pool and 4.0μl of Lipofectamine 
transfection reagent were diluted in separate tubes in Opti-MEM™ (Thermo Fisher 
Scientific, USA) and incubated for 5 min at room temperature (RT). The two solutions 
were then mixed and incubated for further 20 min at RT to form transfection complexes. 
Cells were washed twice with PBS, and then incubated for 4h with the 
siRNA/Lipofectamine complexes before the addition of Opti-MEM™ containing 30% 
FBS without antibiotic. Cells were further incubated at 37°C/5% CO2 for 48h before 
the secretion experiment. Cells were harvested at the appropriate time point for protein 
expression analysis (between 2 and 4 days post transfection). Transfection efficiency 
was quantified by real-time RT-PCR. Sequences of siRNAs and primers are listed in 
Supplementary tables 1A and 1B. 
 
2.4 Protein analysis by Western blot 
Whole-cell protein preparations were obtained from cells grown in 6-well plates at ~80-
90% confluency. After two washes in cold PBS, cells were lysed, on ice, in 150 μl of 
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Triton X-100 lysis buffer, containing phosphatase and protease inhibitors (Sigma 
Aldrich, UK). Lysates were collected by scraping, and cleared from cellular debris by 
centrifugation at 20,000 g, 4°C for 5 min. The supernatants were then collected and 
total protein content quantified before storage at -20°C. Lysates were then analysed by 
SDS/PAGE. 
 
2.5 Immunoblotting and visualisation 
Non-specific antibody binding was prevented by incubating the nitrocellulose 
membranes in PBS-0.05%Tween-20 (v/v, PBS-T) supplemented with 5% milk for 30 
min on a rotating plate. The membranes were then washed with PBS-T followed by an 
overnight incubation with the primary antibody diluted in PBS-T on a rotating plate at 
4°C. After 24h, membranes were washed 5 times for 5 min with PBS-T, and then 
incubated on a rotating plate with the appropriate secondary antibody for 1 h at RT. The 
membranes were then washed with PBS-T, and incubated with ECL Prime solution 
(Amersham Bioscience, UK) or with Immobillon Western Chemiluminescent HRP 
substrate (Merck Millipore, UK) for 5 min, placed in a dark cassette and exposed to 
chemiluminescence film, or directly imaged with a ChemiDoc XRS system. 
 
2.6 Real Time quantitative Polymerase Chain Reaction (RT-qPCR) 
RT-qPCR was performed according to manufacturer’s instructions (Thermo Fisher 
Scientific, USA). Briefly, 100 ng of cDNA were mixed with 7.5 µl of 2X Maxima 
SYBR green/Fluorescein qPCR mix, 1µl of forward and reverse primers (10µM stock) 
to a final volume of 15µl. GADPH cDNAs were also amplified as an internal control. 
All experiments were performed in triplicate. Data were collected at the extension step. 
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The relative changes in gene expression quantification were calculated using the 
relative ddCT analysis mode of the ABI 7500 Real-Time PCR system software.  
The primer pairs used for the amplification of GPR119 and GPR55 were based on 
published sequences [11, 20] and [21] respectively (Supplementary table 1B).   
 
2.7 Primary cell studies 
Mice were euthanized and 5 cm of colon were used for isolation of epithelial cells 
following a previously described protocol [10]. Briefly, colon segments were dissected 
from 10-week-old C57BL/6 male mice. Segments were cut open longitudinally and 
washed quickly in DMEM (serum-free) to remove luminal content. Colon was chopped 
into 1-2 mm pieces and digested with 0.5 mg/ml collagenase-P for 15 min. Resulting 
cell suspensions were filtered through 70 µm nylon cell strainers (BD Falcon, UK), 
centrifuged at 300g for 5 min, and pellets were re-suspended in DMEM supplemented 
with 10% FBS. The purified cells were collected and cultured on 24-well Matrigel-
coated plates at 37°C in DMEM (25 mM glucose), 10% FBS, 2 mM L-glutamine, 100 
IU/ml penicillin and 100 μg/ml streptomycin. On the day of the GLP-1 secretion assay, 
cells were washed twice with PBS, and then treated with LPI or vehicle M:C for 2 h at 
37°C. Supernatants were collected for GLP-1 quantification using the active GLP-1 
ELISA kit from Millipore.  
After euthanasia, pancreatic islets were isolated as described in detail elsewhere [22]. 
Following purification, islets were rested overnight at 37 °C in a humidified atmosphere 
of 95% air and 5% CO2 in RPMI 1640 medium supplemented with 10% FBS, 100 




2.8 Secretion studies  
Approximately 80,000 GLUTag cells were plated on poly-L-lysine–coated 24-well 
culture plates and grown to 80% confluence. NCI-H716 cells were seeded on growth 
factor reduced MatrigelTM (Becton Dickinson, USA) in DMEM medium, supplemented 
with 10% FBS the day before the experiment. For NCI-H716 cells, ~25,000 cells were 
needed for the secretion experiment in order to detect a clear stimulation over low basal 
GLP-1 secretion. In brief, GLUTag and NCI-H716 cells were washed twice and then 
incubated for 2h with serum free DMEM containing 1% vehicle (M:C) alone (negative 
control), 10 µM forskolin as positive control (Sigma-Aldrich, UK), or with different 
concentrations of Oleoyl- LPI.  
For secretion experiments, media and cells were collected separately. In separate 
studies, GLUTag or NCI-H716 cells were pre-treated for 1h with vehicle (DMSO) 
alone (negative control), PD98059 (50 µM; Sigma-Aldrich, UK.), H89 (10 µM; Santa 
Cruz Biotechnology, USA) followed by treatment with Oleoyl-LPI (20µM), OEA 
(10µM), PMA (10µM) or forskolin (10 µM) in the presence of DPP-IV inhibitors, for 
2 h.  
Values of GLP-1 detected in the supernatants were normalized to the number of 
cells/well. Data were then expressed as percentage of basal GLP-1 secretion (GLP-1 
detected in supernatants from cells treated with vehicle alone). 
Glucose-stimulated insulin secretion (GSIS) was performed on hand-picked islets 
placed in groups of five into individual micro centrifuge tubes. Islets were washed 
twice, then incubated with Krebs buffer (KRB, 115 mM NaCl; 4.7 mM KCl; 1.28 mM 
CaCl2
.2H2O; 1.2 mM KH2PO4; 1.2 mM MgSO4
.7H2O; 10 mM NaHCO3; 10 mM 
HEPES; 0.5% BSA; pH 7.4) supplemented with 1.1 mM glucose for 40 min at 37 °C. 
Supernatants were discarded and islets were incubated with KRB supplemented with 
10 
 
16.7 mM glucose in the presence or absence of Oleoyl-LPI for 20 min. Supernatants 
were collected for insulin determination using Mouse Ultrasensitive Insulin ELISA 
(Mercodia, Sweden) according to manufacturer instructions and data was reported as 
picograms of Insulin per islet in 20 min (pg/islet/20min). 
 
2.9 cAMP assay 
COS-7 cells were transfected with 40 µg GPR119 DNA or pcDNA3 per 175m2 flask 
using the calcium-phosphate precipitation method [23]. One day after transfection, 
35,000 cells/well were seeded in a 96 well white plate (Perkin Elmer, USA). The cells 
were washed twice the following day and incubated 30 min at 37°C with HBSS plus 
1mM IBMX (Sigma-Aldrich, USA). Agonists were added for 30 min in the assay 
medium. The Hithunter® cAMP XS+ (DiscoveRx, USA) was carried out following the 
manufactured description [24]. 
 
2.10 Ex-vivo studies 
The GPR55-/- mice were kindly provided by Prof. David Baker (Queen Mary University 
of London) and GPR119-/- were obtained from Taconic. Littermates were used as wild-
type controls. 
3. Results 
3.1 Oleoyl-LPI enhances secretion of GLP-1 from enteroendocrine L-cells   
In order to determine which LPI species is able to modulate GLP-1 secretion from 
enteroendocrine L-cells, murine L-cells GLUTag were stimulated with 20 μM of 
different species of LPI (Arachidonyl-LPI, Stearoyl-LPI, Heptadecenoyl-LPI and 
Oleoyl-LPI). OEA was used as a control based on previous studies reporting due to its 
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role in the secretion of GLP-1 [11, 20]. Forskolin and phorbol 12-myristate 13-acetate 
(PMA) have been reported to potently enhance GLP-1 release in GLUTag [25] and in 
human L-cells NCI-H716 [26], hence they were also chosen as positive controls in these 
experiments. Data indicated that Oleoyl-LPI significantly stimulated GLP-1 secretion 
in GLUTag (Fig. 1 A). Importantly, no increase of GLP-1 secretion was detected upon 
stimulation of GLUTag cells with any of the other LPI species used at the same 
concentration (20µM). Dose response experiments further confirmed increase of GLP-
1 secretion upon stimulation with Oleoyl-LPI from both GLUTag (Fig. 1 B) and NCI-
H716 (Fig. 1 C) cells. 
Interestingly, we observed that Oleoyl-LPI was able to stimulate GLP-1 release much 
more than OEA in these cells. Dose-response analysis of GLP-1 secretion induced by 
Oleoyl-LPI and OEA showed similar EC50 values but different maximal efficacies in 
both GLUTag and NCI-H716 cells (Fig. 1 D and 1 E), suggesting that OEA is only a 
partial agonist of GPR119 compared to Oleoyl-LPI. 
Taken together, these data indicate that Oleoyl-LPI is the specific species of LPI which 
is responsible for the increased GLP-1 secretion from these L-cells. 
 
3.2 Oleoyl-LPI-induced secretion of GLP-1 is not regulated by GPR55 
LPI has been identified as an endogenous ligand for GPR55 [18] with a role in gut 
motility and satiety [27]. Although GPR55 is abundantly expressed along the 
gastrointestinal tract, its potential involvement in GLP-1 regulation has never been 
investigated. Our observation that Oleoyl-LPI potently induced secretion of GLP-1 
raised the question of whether GPR55 was involved in this process. To investigate this, 
GLUTag and NCI-H716 cells were transfected with a specific siRNA targeting GPR55 
or a non-targeting siRNA (siControl). Downregulation of GPR55 was assessed at the 
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protein level by Western blot analysis in both GLUTag and NCI-H716 cells (Fig. 2 A 
and 2 B), as confirmed by densitometry analysis (Fig. 2 C and 2 D) and further validated 
at mRNA levels in GLUTag cells by RT-qPCR (Fig. 2 E). Transfected GLUTag (Fig. 
2 F) and NCI-H716 (Fig. 2 G) cells were then treated with Oleoyl-LPI to assess GLP-
1 secretion. There were no statistically significant differences in Oleoyl-LPI-induced 
GLP-1 secretion between cells transfected with siControl or siGPR55, indicating that 
GPR55 was not involved in mediating GLP-1 secretion upon Oleoyl-LPI stimulation. 
Similarly, treatment of cells with the GPR55 antagonist CID16020046 did not affect 
the Oleoyl-induced GLP-1 secretion (Fig. S1).  
To further validate these results, we investigated the effects of Oleoyl-LPI on a mixed 
colonic primary culture from wild type and GPR55-/- mice, isolated as described 
previously [28-30]. Forskolin was used as positive control in these experiments. Firstly, 
we observed that two hours treatment with Oleoyl-LPI stimulated GLP-1 secretion in 
this ex vivo system, confirming our in vitro results.  
Importantly, no difference in the Oleoyl-LPI-stimulated GLP-1 secretion was detected 
between primary cells isolated from wild type or GPR55-/- mice (Fig. 2 H). Taken 
together, these data indicate that the GLP-1 secretion induced by Oleoyl-LPI is not 
regulated by GPR55. 
 
3.3 GPR119 mediates Oleoyl-LPI-induced GLP-1 secretion from L-cells and 
Insulin secretion from pancreatic β-cells 
We next determined whether GPR119 was required for the Oleoyl-LPI-stimulated 
GLP-1 release. To this end, GLUTag were transiently transfected with a specific siRNA 
targeting GPR119 before stimulation with Oleoyl-LPI. Downregulation of GPR119 
completely inhibited the Oleoyl-LPI-induced GLP-1 secretion (Fig. 3 A). Western blot, 
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and the correspondent densitometric analysis, indicated efficient downregulation of 
GPR119 at protein level in GLUTag cells, which was further confirmed by transcript 
quantification (Fig. 3 B).  Similarly, our data indicate that Oleoyl-LPI-mediated GLP-
1 secretion was dependent on GPR119 in NCI-H716 cells (Fig. S2 A). Efficient 
downregulation of GPR119 in these cells was confirmed by Western blot (Fig. S2 B) 
and RT-qPCR (Fig. S2 B) analysis. We next investigated the effects of Oleoyl-LPI on 
primary cultures of mixed colonic preparation from wild type and GPR119-/- mice. 
Oleoyl-LPI was unable to induce GLP-1 release in cultures derived from GPR119-/- 
mice whereas it potently stimulated GLP-1 secretion in wild type mice (Fig. 3 C). These 
data demonstrate that downregulation of GPR119 in GLUTag and NCI-H716 cells, and 
genetic ablation of GPR119 in mice, impair the Oleoyl-LPI-induced GLP-1 secretion.  
LPI has been shown previously to stimulate insulin secretion from pancreatic β-cells 
[31] directly through a GPR55-independent mechanism [32]. We therefore evaluated 
the ability of pancreatic islets isolated from wild type and GPR119-/- mice to secrete 
insulin in response to Oleoyl-LPI in the presence of glucose. We observed that Oleoyl-
LPI acutely enhanced insulin secretion by approximately 50% in the presence of 16.7 
mM of glucose. Importantly, no secretion of insulin was detected in GPR119-/- islets 
upon stimulation with Oleoyl-LPI (Fig. 3 D), indicating that expression of GPR119 in 
pancreatic islets is necessary for Oleoyl-LPI stimulation of insulin secretion.  
 
3.4 Intracellular ERK1/2 activation is involved in Oleoyl-LPI-induced GLP-1 
secretion  
It has been reported that phosphorylation of ERK1/2 is involved in GLP-1 secretion 
mediated by several ligands [8, 33, 34]. In order to determine whether Oleoyl-LPI 
activated ERK1/2 in the enteroendocrine L-cells we assessed its phosphorylation state 
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over a time course experiment. Oleoyl-LPI stimulation increased phosphorylation of 
ERK1/2 at residues Thr202 and Tyr204 within 10 min (Fig. 4 A). To determine whether 
GPR119 was involved in this Oleoyl-LPI-mediated ERK1/2 activation, GLUTag cells 
transfected with siGPR119 or siControl were stimulated for up to 10 min with Oleoyl-
LPI, and phosphorylation of ERK1/2 was assessed by Western blot. Data indicated a 
clear inhibition of ERK1/2 activation in cells transfected with siGPR119, as confirmed 
by densitometric analysis (Fig. 4 B). Similarly, downregulation of GPR119 inhibited 
ERK1/2 phosphorylation upon stimulation with Oleoyl-LPI in NCI-H716 cells (Fig. 
S2C). These data indicate that Oleoyl-LPI stimulates ERK1/2 activation in L-cells 
through GPR119. To determine whether the detected activation of the mitogen 
activated protein kinase (MAPK) signalling pathway was involved in regulation of 
GLP-1 secretion, GLUTag (Fig. 4 C) and NCI-H716 (Fig. 4 D) cells were pre-treated 
with the mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor PD98059 for 1h 
prior to Oleoyl-LPI stimulation. The inhibitor was kept in the medium throughout the 
secretion experiment.  
Treatment of GLUTag and NCI-H716 cells with PD98059 partially but significantly 
reduced Oleoyl-LPI-induced ERK1/2 phosphorylation and GLP-1 secretion (Fig. 4 C 
and 4 D). These data indicate that the Oleoyl-LPI-dependent, GPR119-mediated 
secretion of GLP-1 is partially regulated through activation of ERK1/2. 
 
 
3.5 Oleoyl-LPI stimulates cAMP production in COS-7 cells and activates CREB 
in enteroendocrine L-cells 
Previous studies have demonstrated that activation of PKA is able to stimulate 
proglucagon gene transcription and GLP-1 synthesis in GLUTag cells and primary 
foetal rat intestinal cultures [35, 36]. Furthermore, ligand binding to GPR119 activates 
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stimulatory G proteins that signal via adenylate cyclase to increase cAMP levels and 
activate PKA [15]. To determine whether Oleoyl-LPI was able to increase intracellular 
cAMP levels through GPR119, we used COS-7 cells overexpressing GPR119. 
Treatment with Oleoyl-LPI increased the production of cAMP similarly to OEA with 
comparable EC50s (Oleoyl-LPI 236 nM and OEA 217 nM, Fig. S 3). To determine 
whether the Oleoyl-LPI-mediated secretion of GLP-1 was dependent on increased 
cAMP levels, GLUTag and NCI-H716 cells were pre-treated with the PKA inhibitor, 
H-89 (10 μM) before stimulation. PKA inhibition suggested a hampered Oleoyl-LPI-
induced GLP-1 secretion, although data were not statistically significant (Fig. 5 A and 
5 B). On the other hand, simultaneous inhibition of MEK1/2 (using PD98059) and PKA 
(using H-89) completely abolished the Oleoyl-LPI-induced GLP-1 release in GLUTag 
cells (Fig. S 4). Interestingly, we observed that inhibition of PKA reduced partially the 
Oleoyl-LPI-dependent ERK1/2 phosphorylation (Fig. S5), suggesting a contribution of 
the cAMP/PKA pathway on ERK1/2 activation. Taken together these data indicate that 
total inhibition of Oleoyl-LPI mediated ERK1/2 signalling (as achieved by treatment 
with PD98059) only partially inhibits GLP-1 secretion whereas partial inhibition of 
ERK1/2 (as achieved by treatment with H-89) is not sufficient to appreciably affect it. 
On the other hand, combination of full ERK1/2 inhibition (by PD98059) and PKA 
inhibition (by H-89) completely blocks the Oleoyl-LPI-dependent GLP-1 secretion. 
It is known that the increase of proglucagon gene transcription in L-cells is regulated 
by a cAMP-response element (CRE) in the 5’-flanking sequence of the gene [37]. 
CREB is a cellular transcription factor that binds to CRE to regulate the transcription 
of proglucagon.  
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Interestingly, we noticed that phosphorylation of CREB at its residue Ser133 was 
stimulated by treatment with Oleoyl-LPI in both GLUTag (Fig. 5C) and NCI-H716 
(Fig. 5D) cells.  
Taken together these data suggest that Oleoyl-LPI stimulates cAMP production that 
subsequently triggers PKA activation and phosphorylation of CREB through GPR119. 
Considering that the single blockade of PKA does not effectively modulate exocytosis, 
but on top of a MEK1/2 inhibition completely abolishes any Forskolin or Oleoyl-LPI 




It has been reported that both pancreas and gastrointestinal tract express high levels of 
GPR55, and GPR119.  Recently, the lysophospholipid LPI was identified as a ligand 
for GPR55 and we hypothesized that GPR119 could be another potential LPI receptor. 
For instance, it has been reported that LPI can activate GPR119 in RH7777 rat 
hepatoma cells stably expressing human GPR119 [11]. Activation of GPR119 in the 
pancreas is correlated with enhanced glucose stimulated insulin secretion and activation 
of this receptor in the gut results in increased secretion of incretin hormones GLP-1 and 
GIP [4, 38]. These observations suggest that GPR119 activation may reduce blood 
glucose levels by acting on L-cells to stimulate GLP-1 release that in turn stimulate β-
cells to promote glucose stimulated insulin secretion. Therefore, activation of this 
receptor by Oleoyl-LPI could be an interesting therapeutic target for treatment of T2D. 
The overall aim of this study was to explore the potential role of LPI in the secretion of 
17 
 
GLP-1 by enteroendocrine L-cells through the activation of GPR119, and the 
mechanism underlying this process. 
Our study demonstrated that Oleoyl-LPI increases GLP-1 secretion in-vitro and in ex-
vivo preparations of enteroendocrine L-cells. Previous reports have demonstrated that 
fatty acids containing an oleoyl chain such as Oleoylethanolamide (OEA) and 2-
Oleoyl-glycerol (2-OG) can enhance secretion of GLP-1 by enteroendocrine cells [4, 
20]. Oleoyl-LPI is an endogenous phospholipid with an inositol head and an acylated 
Oleoyl chain (18:1). A heterogeneous mixture of different species of LPI, with distinct 
acyl chains, primarily saturated, was initially described as the endogenous ligand for 
GPR55 [18]. This LPI-GPR55 binding, similarly to multiple cannabinoids, is reported 
to activate a downstream Gα13/RhoA/ROCK-dependent Calcium signalling [39]. More 
recently, the presence of the cation channel TRPV2 was found to be necessary for the 
activation of this pathway [40]. Nonetheless, the stimulation of GPR55 with the 
synthetic agonist O-1605, fails to mimic the reported LPI activity, indicating the 
involvement of other molecular players.  
Indeed, the data reported by the authors, clearly indicate only a minor involvement of 
GPR55 in the LPI-mediated secretion of GLP-1, and fail to address the composition of 
the LPI mixture [40].  
There is currently no available information regarding the activity of specific LPI 
species. Here we show that GPR55, contrarily to GPR119, is dispensable for the 
Oleoyl-LPI-mediated secretion of GLP-1.  
Another interesting finding that we report is that Oleoyl-LPI displays a much higher 
GLP-1 secreting activity than OEA (Fig. 1 D and 1 E), despite similar cAMP raising 
capabilities (Fig. S 3). These data appeared to be in contrast with those of Lauffer et al. 
[20] which concluded that OEA induced GLP-1 secretion when tested at the same 
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concentration (10μM). Noticeably, these authors maintained the GLUTag cells culture 
in a higher glucose concentration of 25 mM and not at a level (5.5mM) normally used 
for this cell line [25, 35, 37, 41, 42] therefore the possible interference of high glucose 
cannot be ruled out. A recent study [43] revealed that GLUTag cells cultured in high 
glucose concentration had increased total production and release of active GLP-1, 
reactive oxygen species and upregulated proglucagon mRNA expression. Our data 
further demonstrated that GPR119 is required for the Oleoyl-LPI-mediated GLP-1 
secretion (Fig. 3).  
Consistent with previous reports of an association between increased accumulation of 
cAMP and GLP-1 secretion [25, 44, 45], we hypothesized that Oleoyl-LPI may regulate 
GPR119 activation and secretion of GLP-1 secretion through the cAMP/PKA/CREB 
pathway. Pharmacological inhibition of PKA by H-89 was able to reduce Oleoyl-LPI-
induced GLP-1 secretion only slightly. Because the reduction of GLP-1 secretion is not 
statistically significant (Fig. 5), this indicates that Oleoyl-LPI-mediated activation of  
CREB is partially dispensable for the secretion of GLP-1 in this system. 
In addition, our data show that Oleoyl-LPI induced GLP-1 secretion primarily depends 
on ERK 1/2 activation. Pharmacological blockade of MEK 1/2 with PD98059 
significantly inhibited Oleoyl-LPI mediated GLP-1 secretion (Fig. 4 C and 4 D), but 
synergism with PKA appears essential for maximal GPR119 mediated GLP-1 secretion 
(Supplementary Fig. 4). 
5. Conclusion 
This study demonstrated that Oleoyl-LPI is the specific species of LPI that is involved 
in the regulation of GLP-1 secretion from enteroendocrine L-cells. We have identified 
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a signalling pathway involving GPR119 activation, that signals downstream through 
both the ERK1/2 and the cAMP/PKA/CREB pathway (Fig. 5). 
 The pharmacology of Oleoyl-LPI could be explored, not only as a specific GPR119 
agonist, but also for further development of metabolically stable mimics for the 
enhancement of endogenous GLP-1 secretion, and subsequent improvement of glucose 
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Appendix A. Supplementary data  
Fig. S1 Shows that pharmacological inhibition of GPR55 does not affect Oleoyl-LPI-
mediated GLP-1 secretion in GLUTag and NCI-H716 cells. 
Fig. S2 Displays the ablation of GLP-1 response in NCI-H716 cells transfected with 
siRNA targeting GPR119. The panel S2B shows a representative Western Blot, and 
transcript quantification analysis indicating the efficient downregulation of GPR119 
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expression. S2C further indicates the siGPR119-mediated blockage inhibition of 
ERK1/2 activation.  
Fig. S3 Shows a cAMP dose-response curve in GPR119 expressing COS-7 cells treated 
with increasing amounts of Oleoyl-ethanolamide (OEA) red circles, or Oleoyl-LPI, 
black squares. The two drugs display similar Log EC50s.  
Fig. S4 Indicates the complete blockage of GLP-1 secretion upon the simultaneous 
treatment with PKA and MEK1/2 inhibitors. 
Fig. S5 are two typical western blots showing that PKA activity is required for a full 
Oleoyl-LPI mediated ERK1/2 activation 
Table. S1 shows the sequences utilized for (S1 A) knockdown and (S1 B) Real Time 
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Figure 1: Oleoyl-LPI enhances GLP-1 secretion in vitro.  
 (A) GLUTag cells were incubated with the indicated species of LPI (20μM) or vehicle 
alone for 2h. Alternatively, GLUTag (B) and NCI-H716 (C) cells were incubated with 
increasing concentrations of Oleoyl-LPI. In these experiments, OEA and Forskolin 
were used as positive controls. Secretion of GLP-1 was assessed by ELISA as described 
in the Materials and Methods section. Data are expressed as percentage of values from 
cells treated with vehicle alone.  
 (D, E) Dose-response curves of Oleoyl-LPI (closed circles) and OEA (open squares) 
in GLUTag (D) and NCI-H716 cells (E) normalized to Oleoyl-LPI 100 μM. The two 
compounds display different maximal efficacies but similar potencies, with EC50s 
around 30 μM in both GLUTag and NCI-H716. In all panels data are means ± SEM of 
at least 3 independent experiments. Statistical significance was assessed via One-way 
ANOVA followed by a post hoc Dunnet analysis for graphs A, B and C, and Two-way 
ANOVA with post hoc Sidak test for dose-responses in D and E. Statistical significance 
is indicated as: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
 
Figure 2: Oleoyl-LPI-induced secretion of GLP-1 is not regulated by GPR55. 
Representative Western blot showing downregulation of GPR55 in GLUTag (A) and 
NCI-H716 (B) at 48h post transfection with a specific siRNA targeting GPR55 or a 
non-targeting siRNA (siControl). Tubulin was used as loading control. Corresponding 
densitometry analysis are shown in (C) and (D) respectively. (E) mRNA levels of 
GPR55 in GLUTag cells transfected with the indicated siRNAs (48h post transfection). 
(F, G) GLP-1 secretion from GLUTag (F) or NCI-H716 (G) cells transfected with the 
indicated siRNAs and stimulated with 20 μM Oleoyl-LPI (+) or vehicle alone (-) 48h 
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post transfection. Data are expressed as percentage of values from cells transfected with 
siControl and treated with vehicle. (H) Secretion of GLP-1 by mixed primary colonic 
culture from wild type (C57BL/6) and C57BL/6 GPR55-/- mice upon stimulation with 
Oleoyl-LPI or vehicle alone. Forskolin was used as positive control. Results are 
normalized to the respective vehicle (control). Data are means ± SEM of at least n = 3 
independent experiments. Statistical significance for panels C, D, E was assessed with 
one-sided t student tests, and for F, G and H with Two-way ANOVAs followed by 
Sidak test: Significance was assumed for *p<0.05, **p<0.01, ***p<0.001   
 
Figure 3: GPR119 mediates Oleoyl-LPI-induced GLP-1 and insulin secretion in 
vitro and ex-vivo.  
(A) Secretion of GLP-1 from GLUTag stimulated with 20 μM Oleoyl-LPI at 48h post 
transfection with the indicated siRNAs. Data are expressed as percentage of values 
from cells transfected with siControl and treated with vehicle and are means ± SEM of 
at least n=3 independent experiments performed in duplicates. Two-way ANOVA with 
Sidak post hoc test ** p<0.01. (B) Results from RT-qPCR (top right panel), and 
representative Western blot analysis and densitometry (bottom right panel) confirming 
the downregulation of GPR119 mRNA and protein levels in GLUTag cells at 48 h post 
transfection. In the blot tubulin was used as loading control. One-tail Student t-test: ** 
p<0.01, ***p<0.001. (C) 10 μM Oleoyl-LPI-induced secretion of GLP-1 in mixed 
primary colonic culture derived from wild type and GPR119-/- mice. Results are 
normalized to data obtained in cultures incubated with vehicle (control). Averages of 3 
independent experiments are shown ± SEM.  
 (D) Following isolation from wild type, or GPR119-/- mice, pancreatic islets were 
rested overnight. Glucose-stimulated insulin secretion analysis was performed by 
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incubating islets with 16.7 mM of glucose in the presence or absence of Oleoyl-LPI (20 
µM) for 20 min. Tissues from 4 different animals were used in independent 
experiments.  
Two-way ANOVA with Sidak post hoc test was used to assess statistical significance 
in C and D: * p<0.05, ** p<0.01. 
 
Figure 4: Activation of ERK1/2 is required for the Oleoyl-LPI-induced GLP-1 
secretion 
(A) Quantitative analysis of ERK1/2 phosphorylation upon treatment of GLUTag cells 
with Oleoyl-LPI for the indicated times. A representative blot is also shown (B). 
GLUTag were transfected with the indicated siRNAs before stimulation with Oleoyl-
LPI for the indicated times. Results from densitometric analysis of ERK1/2 
phosphorylation and a representative Western blot are shown. (C, D) GLUTag (C) and 
NCI-H716 (D) were pre-treated with the MEK 1/2 inhibitor PD98059 (50µM) for 1h 
prior to the stimulation with Oleoyl-LPI, Forskolin, PMA or vehicle alone always in 
presence of the inhibitor. “Control” cells were pre-treated with DMSO. GLP-1 
secretion was assessed as above. Data are expressed as percentage of values from 
control cells treated with vehicle and are expressed as means ± SEM of n=3 independent 
experiments. One-way ANOVA post hoc Dunnett test for data in A, and Two-way 
ANOVA with post hoc Sidak test for figures B, C and D: *p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. At the end of the secretion experiments, cells were lysed to 
confirm efficacy of MEK1/2 inhibitor, assessing ERK1/2 phosphorylation by Western 




Figure 5: Oleoyl-LPI activates cAMP response-element binding (CREB) in 
enteroendocrine L-cells.  
(A,B) Oleoyl-LPI-, Forskolin- and PMA-induced GLP-1 secretion in GLUTag (A) and 
NCI-H716 cells (B) treated with the synthetic PKA inhibitor H-89 (10µM). “Control 
cells” were treated with DMSO. Data are expressed as percentage of “control cells” 
treated with vehicle and are means ± SEM of n=3 independent experiments performed 
in duplicates. Student t-test: n.s. p>0.05. (C,D) Representative Western blots and 
corresponding densitometric analysis of CREB phosphorylation at its residue Serine 
133 in GLUTag (C) and NCI-H716 (D) cells. Cells were pre-treated with 10 μM H-89 
before stimulation with 20 μM Oleoyl-LPI, 10μM Forskolin or 10 μM PMA in the 
presence or absence of H-89.  
Data are from n=3 independent experiments. Two-Way ANOVA with Sidak post hoc 
test *p<0.05, **p<0.01. 
 
Supplementary Figure 1: Pharmacological inhibition of GPR55 does not inhibit the 
Oleoyl-LPI-mediated GLP-1 secretion. GLUTag and NCI-H716 cells were pre-
treated for 30 min with 5 μM CID16020046, followed by 2h stimulation with 10 μM 
Oleoyl-LPI in the presence or absence of CID16020046 (5 μM). Secreted GLP-1 levels 
were quantified via ELISA. Data are from n=2 independent experiments.  
 
Supplementary Figure 2: Oleoyl-LPI-induced GLP-1 secretion requires GPR119 in 
human NCI-H716. 
(A) Oleoyl-LPI treatment (20μM) and GLP-1 secretion quantification in NCI-H716 
cells transfected with a specific siRNA targeting GPR119. (B) Representative Western 
Blot and transcript quantification analysis in transfected NCI-H716 cells. (C) siRNA-
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mediated downregulation of GPR119 inhibits Oleoyl-LPI mediated phosphorylation of 
ERK1/2. Densitometric analysis of n=3 independent experiments are shown. Statistical 
significance was assessed via Two-way ANOVA with post hoc Sidak test in S1A and 
one-way Student-t test for S1C. 
 
Supplementary Figure 3: Oleoyl-LPI induces cAMP accumulation in GPR119 
expressing COS-7 cells.  
cAMP dose-response curve in GPR119 expressing COS-7 cells treated with increasing 
concentrations of Oleoyl-ethanolamide (OEA) red circles, or Oleoyl-LPI, black 
squares. The two drugs display similar Log EC50s.  
 
Supplementary Figure 4: Effect of MEK and PKA inhibition in GLUTag cells on 
GLP-1 secretion 
GLUTag were pre-treated for 1h with PD98059 (50 μM) alone (A), or in combination with 
H-89 (10 μΜ) (B) before treatment with Oleoyl-LPI (10 μM) or vehicle for 2h. Results of 
active GLP-1 released are expressed as percentage increase compared to the vehicle (DMSO 
+ M:C). Data are means ± SEM of n=3 independent experiments performed in duplicate.  
 
Supplementary Figure 5: Immunoblot analysis of H-89 PKA-mediated ERK1/2 
modulation. A representative blot is shown for GLUTag and NCI-H716 cells pre-
treated with 10 μM H-89 for 1h, and then treated with Forskolin 10 μΜ, or PMA 10 
μM, and Oleoyl-LPI 10 μM for 10 min in presence of H-89 10 μM. PKA blockage 









































Supplementary Tables  
 















 Supplementary table 1 A: Sequences of siRNAs used in Knockdown experiments 
 
Target gene Forward Reverse 
Human GPR119 TCTCGGCCCACACAGAAGA GCTGCGGAGGAAGTGACAAA 
Murine GPR119 TGATGGTGTTGGCCTTTGCTTCAC TGGTAAAGGCAGCATTTGTGGCAG 
Human GPR55 GTTTCCATGGGAAAGTGGAA GGAAGGAGACCACGAAGACA 
Murine GPR55 CTATCTACATGATCAACTTGGCTGTTT TGTGGCAGGACCATCTTGAA 
Human GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA 
Murine GAPDH GCACAGTCAAGGCCGAGAAT GCCTTCTCCATGGTGGTGAA 
Supplementary table 1 B: Sequences of Primers used in RT-PCR  
 
 
 
